Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Overview
- Overall Price Differentials Among Markets
- Pricing Hierarchy in Individual Markets
- Price Variations by Therapeutic Area
- Cardiovascular Drugs
- Metabolic Disease Therapies
- Immune and Infl ammatory Disease Therapies
- Infectious Disease Therapies
- Neurology Drugs
- Psychiatric Drugs
- Antineoplastic Drugs
- Treatments for the Side Effects of Chemotherapy
- Gastrointestinal Drugs
- Prices of Biologics
- Outlook and Implications for the Pharmaceutical Industry
Tables
- 1. Dosages Used for Pricing Calculations
- 2. Ex-Manufacturer Prices of Select Best-Selling Prescription Drugs
Expressed as a Percentage of U.S. Prices
- 3. U.S. Prices as a Percentage of Average Prices in the Other Six Major
Pharmaceutical Markets
- 4. French Prices as a Percentage of U.S. Prices
- 5. German Prices as a Percentage of U.S. Prices
- 6. Italian Prices as a Percentage of U.S. Prices
- 7. Spanish Prices as a Percentage of U.S. Prices
- 8. U.K. Prices as a Percentage of U.S. Prices
- 9. Average European Prices as a Percentage of U.S. Prices
- 10. Japanese Prices as a Percentage of U.S. Prices
- 11. Prices of Leading Cardiovascular Drugs in the Major Markets as a
Percentage of U.S. Prices
- 12. Prices of Leading Metabolic Disease Therapies in the Major Markets as
a Percentage of U.S. Prices
- 13. Prices of Leading Immune and Infl ammatory Disease Therapies in the
Major Markets as a Percentage of U.S. Prices
- 14. Prices of Leading Infectious Disease Therapies in the Major Markets as
a Percentage of U.S. Prices
- 15. Prices of Leading Neurological Disease Therapies in the Major Markets
as a Percentage of U.S. Prices
- 16. Prices of Leading Psychiatric Drugs in the Major Markets as a
Percentage of U.S. Prices
- 17. Prices of Leading Antineoplastic Drugs in the Major Markets as a
Percentage of U.S. Prices
- 18. Prices of Leading Treatments for the Side Effects of Chemotherapy in
the Major Markets as a Percentage of U.S. Prices
- 19. Prices of Leading Gastrointestinal Drugs in the Major Markets as a
Percentage of U.S. Prices
- 20. Prices of Leading Biologics in the Major Markets as a Percentage of
U.S. Prices
Figures
- 1. Average Prices of Leading Cardiovascular Drugs in the Major Markets as
a Percentage of U.S. Prices
- 2. Average Prices of Leading Metabolic Disease Therapies in the Major
Markets as a Percentage of U.S. Prices
- 3. Average Prices of Leading Immune and Infl ammatory Disease Therapies in
the Major Markets as a Percentage of U.S. Prices
- 4. Average Prices of Leading Infectious Disease Therapies in the Major
Markets as a Percentage of U.S. Prices
- 5. Average Prices of Leading Neurological Disease Therapies in the Major
Markets as a Percentage of U.S. Prices
- 6. Average Prices of Leading Psychiatric Disease Therapies in the Major
Markets as a Percentage of U.S. Prices
- 7. Average Prices of Leading Antineoplastic Drugs in the Major Markets as
a Percentage of U.S. Prices
- 8. Average Prices of Leading Treatments for the Side Effects of
Chemotherapy in the Major Markets as a Percentage of U.S. Prices
- 9. Average Prices of Leading Gastrointestinal Drugs in the Major Markets
as a Percentage of U.S. Prices
- 10. Average Prices of Leading Biologics, Small-Molecule Drugs, and
Pharmaceuticals Overall in the Major Markets as a Percentage of U.S. Prices
|
Related Report
|
View Cart
